KR20240118915A - 항-타우 항체 조성물, 투여 형태 및 방법 - Google Patents

항-타우 항체 조성물, 투여 형태 및 방법 Download PDF

Info

Publication number
KR20240118915A
KR20240118915A KR1020247018587A KR20247018587A KR20240118915A KR 20240118915 A KR20240118915 A KR 20240118915A KR 1020247018587 A KR1020247018587 A KR 1020247018587A KR 20247018587 A KR20247018587 A KR 20247018587A KR 20240118915 A KR20240118915 A KR 20240118915A
Authority
KR
South Korea
Prior art keywords
antibody
tau
dose
human subject
tauopathy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018587A
Other languages
English (en)
Korean (ko)
Inventor
라리사 레이더만
서밋 라왈
크리스틴 루스 와일드스미스
진 저우
파우 아세베스 발도
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20240118915A publication Critical patent/KR20240118915A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020247018587A 2021-11-03 2022-11-03 항-타우 항체 조성물, 투여 형태 및 방법 Pending KR20240118915A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163275045P 2021-11-03 2021-11-03
US63/275,045 2021-11-03
US202163290278P 2021-12-16 2021-12-16
US63/290,278 2021-12-16
US202263316582P 2022-03-04 2022-03-04
US202263316616P 2022-03-04 2022-03-04
US63/316,616 2022-03-04
US63/316,582 2022-03-04
PCT/IB2022/060604 WO2023079485A1 (en) 2021-11-03 2022-11-03 Anti-tau antibody compositions, dosage forms, and methods

Publications (1)

Publication Number Publication Date
KR20240118915A true KR20240118915A (ko) 2024-08-05

Family

ID=84360026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018587A Pending KR20240118915A (ko) 2021-11-03 2022-11-03 항-타우 항체 조성물, 투여 형태 및 방법

Country Status (8)

Country Link
EP (1) EP4426336A1 (https=)
JP (1) JP2024540226A (https=)
KR (1) KR20240118915A (https=)
AU (1) AU2022381556A1 (https=)
CA (1) CA3237660A1 (https=)
MX (1) MX2024005430A (https=)
TW (1) TW202334201A (https=)
WO (1) WO2023079485A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137359A1 (en) 2023-12-20 2025-06-26 Eisai R&D Management Co., Ltd. Assay methods to identify a disease
CN117946264B (zh) * 2024-03-21 2024-06-04 江西赛基生物技术有限公司 一种抗Tau蛋白单克隆抗体及其应用
WO2026015877A1 (en) 2024-07-12 2026-01-15 Eisai R&D Management Co., Ltd. Fluid biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074420A2 (en) * 2013-11-27 2016-10-05 Ipierian, Inc. Methods of treating a tauopathy
MA48595A (fr) * 2016-12-07 2020-03-18 Ac Immune Sa Anticorps anti-tau et leurs méthodes d'utilisation
EP3697814A1 (en) 2017-10-16 2020-08-26 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20240101654A1 (en) * 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Also Published As

Publication number Publication date
AU2022381556A1 (en) 2024-05-02
CA3237660A1 (en) 2023-05-11
EP4426336A1 (en) 2024-09-11
JP2024540226A (ja) 2024-10-31
WO2023079485A1 (en) 2023-05-11
TW202334201A (zh) 2023-09-01
MX2024005430A (es) 2024-05-21

Similar Documents

Publication Publication Date Title
KR20240118915A (ko) 항-타우 항체 조성물, 투여 형태 및 방법
TW201945401A (zh) 降低心血管風險的方法
CN112996561A (zh) 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
CN118591389A (zh) 使用萨特利珠单抗治疗中枢神经系统（cns）的脱髓鞘疾病
KR20240049351A (ko) Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
WO2023111618A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
TW202543674A (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20240352109A1 (en) Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof
US20230183362A1 (en) Methods for treating prurigo nodularis by administering an il-4r antagonist
TW202325728A (zh) 治療阿茲海默症之方法
CN118215497A (zh) 抗tau抗体组合物、剂型和方法
CN117999094A (zh) 抗Aβ初原纤维抗体的皮下配制品及其使用方法
TW202313111A (zh) 治療阿茲海默症之方法
TW202513583A (zh) 使用抗Ａβ初原纖維抗體之治療方法
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
WO2025240435A1 (en) Methods of treating neurological disorders with anti-abeta antibodies
KR20240067001A (ko) 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
WO2025064824A1 (en) Methods for treating alzheimer's disease
JP2021183633A (ja) 再発型の多発性硬化症を治療するための方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240603

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application